Commercialising the science of the Babraham Institute




The Babraham Institute aims to maximise the impact of its scientific discoveries; where appropriate this is achieved through commercialisation of its intellectual property rights. This primarily involves licensing new discoveries and technologies to pharma and biotech companies, but in some cases commercialisation is achieved through spinning out new companies (for example Crescendo Biologics Ltd).

Current opportunities for licensing the Babraham Institute’s intellectual property include:


Enhancing the potency of stem cells Download flier
International patent applications filed in USA, Europe, Japan, Australia, Canada, China. (priority date 17th December 2012) Worldwide

VDJ-Seq Download flier
International patent applications filed in Europe, USA and Japan (priority date 2nd March 2012) Non-exclusive, worldwide

Capture Hi-C: Deciphering the 3D folding of the genome
Please contact us for further details.
Priority patent application filed 5th September 2013. Worldwide


All available via Ximbio

Monoclonal antibody against 5-hydroxymethylcytosine
Non-exclusive, worldwide
Ficz et al (2010) Nature 473, 398-402

Conditional p110δ knockout mice
Non-exclusive, worldwide
Rolf et al (2010) J Immunol 185(7), 4042-52

Germline p110δ knockout mice
Non-exclusive, worldwide
Clayton et al (2002) J Exp Med 196(6), 753-63

Tau P301L knockin mice
Non-exclusive, worldwide
Gilley et al (2012) Neurobiol Aging 33 621.e1-621.e15

Nmnat2-Venus transgenic mice
Non-exclusive, worldwide
Milde et al (2013) Sci Rep 3, 2567


Crescendo Biologics Ltd was spun out of the Babraham Institute in 2008. The company is focussed on developing a transgenic mouse platform for the in vivo generation of human, high-affinity, soluble, VH antibody fragments, the smallest fragments that retain antibody binding and have many desirable properties as potential therapeutics. In 2010 the company announced the generation of the first “triple-knockout” mouse, and in late 2013 it received £19.5M Series A funding. Crescendo Biologics is based on the Babraham Research Campus, and continues to collaborate with Institute scientists.

Monoclonal Antibody against 5-hmC

A reagent specific for 5-hydroxymethylcytosine (5-hmC) was developed by Babraham’s monoclonal antibody laboratory in collaboration with Professor Adrian Bird at the University of Edinburgh and Professor Wolf Reik’s group at Babraham. 5-hmC is a novel type of epigenetic modification enriched in euchromatic areas of the genome and associated with increased gene expression.

The monoclonal antibody developed has proved of value for assays of this epigenetic mark and has now been licensed non-exclusively to several companies.


Contact Us

Evans-RobertsPlease contact us if you are interested in licensing Babraham Institute discoveries.

Dr Katy Montague, Commercialisation Manager
+44 (0)1223 496208